• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CHRS

CHRS

Coherus Oncology, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.47

-0.05 (-3.29%)

Rating:D+

Company Profile

CEO

Dennis Lanfear

IPO Date

2014-11-06

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.52

Prev. Close

$1.52

Day Low

$1.46

Day High

$1.52

52W Low

$0.71

52W High

$2.62

Market Cap

$0.18B

Volume

1.04M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

31.1%

Avg Negative

3.9%

Avg Neutral

65.0%

News Feed

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

GlobeNewsWire·8/18/2021·↑ positive

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/8/2021·↓ negative

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·8/5/2021·↑ positive

Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research·7/29/2021·↑ positive

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

GlobeNewsWire·7/26/2021·↑ positive

Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial

Benzinga·6/4/2021·↑ positive

CHRS Stock Price: Over 10% Increase Pre-Market Explanation

Pulse2·6/4/2021·↑ positive

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/10/2021·↓ negative

Coherus BioSciences to Present at the Bank of America Health Care Conference

GlobeNewsWire·5/7/2021·↑ positive

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive